4//SEC Filing
BIOASIA INVESTMENTS IV LLC 4
Accession 0001615774-19-008214
CIK 0001484565other
Filed
May 20, 8:00 PM ET
Accepted
May 21, 8:55 PM ET
Size
13.7 KB
Accession
0001615774-19-008214
Insider Transaction Report
Form 4
BIOASIA MANGEMENT LLC
10% Owner
Transactions
- Sale
Common Stock
2019-05-17$1.98/sh−1,492$2,954→ 9,856 total(indirect: See Footnote) - Sale
Common Stock
2019-05-17$1.98/sh−10,434$20,659→ 68,942 total(indirect: See Footnote) - Sale
Common Stock
2019-05-20$1.92/sh−9,856$18,924→ 0 total(indirect: See Footnote) - Sale
Common Stock
2019-05-20$1.92/sh−68,942$132,369→ 0 total(indirect: See Footnote)
BIOASIA INVESTMENTS IV LLC
10% Owner
Transactions
- Sale
Common Stock
2019-05-17$1.98/sh−1,492$2,954→ 9,856 total(indirect: See Footnote) - Sale
Common Stock
2019-05-20$1.92/sh−9,856$18,924→ 0 total(indirect: See Footnote) - Sale
Common Stock
2019-05-17$1.98/sh−10,434$20,659→ 68,942 total(indirect: See Footnote) - Sale
Common Stock
2019-05-20$1.92/sh−68,942$132,369→ 0 total(indirect: See Footnote)
Footnotes (4)
- [F1]The shares of common stock are held directly by Biotechnology Development Fund II, L.P. ("BDF II"). BioAsia Management, LLC is the sole general partner of BDF II, and may be deemed to beneficially own the shares of common stock owned by BDF II. BioAsia Management, LLC disclaims beneficial ownership of the shares of Soleno Therapeutics held by BDF II, except to the extent of its pecuniary interest therein. The voting members of BioAsia Management LLC are Frank Kung, Edgar Engleman and Anselm Leung, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.
- [F2]The shares of common stock are held directly by Biotechnology Development Fund IV, L.P., Biotechnology Development Fund IV Affiliates, L.P., and BDF IV Annex Fund, L.P. (collectively, "Vivo Fund IV"). BioAsia Investments IV, LLC is the general partner of Vivo Fund IV and may be deemed to be beneficially own such shares. The voting members of BioAsia Investments IV, LLC are Frank Kung and Edgar Engleman, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.
- [F3]The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.89 to $2.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
Documents
Issuer
SOLENO THERAPEUTICS INC
CIK 0001484565
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001261786
Filing Metadata
- Form type
- 4
- Filed
- May 20, 8:00 PM ET
- Accepted
- May 21, 8:55 PM ET
- Size
- 13.7 KB